Lipocine (LPCN) Stock Overview
A clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
LPCN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Lipocine Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.40 |
| 52 Week High | US$12.37 |
| 52 Week Low | US$2.52 |
| Beta | 1.02 |
| 1 Month Change | -21.53% |
| 3 Month Change | 41.49% |
| 1 Year Change | 123.40% |
| 3 Year Change | 35.27% |
| 5 Year Change | -71.92% |
| Change since IPO | -97.82% |
Recent News & Updates
Recent updates
Lipocine announces plans to focus on treating CNS disorders, shares rise ~5%
Sep 26Does Lipocine (NASDAQ:LPCN) Have A Healthy Balance Sheet?
Feb 22
Is Lipocine (NASDAQ:LPCN) Using Debt Sensibly?
Sep 14When Will Lipocine Inc. (NASDAQ:LPCN) Turn A Profit?
May 11Lipocine Inc. (NASDAQ:LPCN): Are Analysts Optimistic?
Jan 26Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?
Dec 04
Shareholder Returns
| LPCN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.2% | -0.02% | -1.6% |
| 1Y | 123.4% | 22.2% | 15.2% |
Return vs Industry: LPCN exceeded the US Pharmaceuticals industry which returned 23.1% over the past year.
Return vs Market: LPCN exceeded the US Market which returned 15.9% over the past year.
Price Volatility
| LPCN volatility | |
|---|---|
| LPCN Average Weekly Movement | 15.0% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: LPCN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LPCN's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 14 | Mahesh Patel | www.lipocine.com |
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management.
Lipocine Inc. Fundamentals Summary
| LPCN fundamental statistics | |
|---|---|
| Market cap | US$54.24m |
| Earnings (TTM) | -US$9.63m |
| Revenue (TTM) | US$1.98m |
Is LPCN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LPCN income statement (TTM) | |
|---|---|
| Revenue | US$1.98m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.98m |
| Other Expenses | US$11.60m |
| Earnings | -US$9.63m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.32 |
| Gross Margin | 100.00% |
| Net Profit Margin | -487.05% |
| Debt/Equity Ratio | 0% |
How did LPCN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/26 13:00 |
| End of Day Share Price | 2026/03/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lipocine Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| John Newman | Canaccord Genuity |
| Corey Davis | Canaccord Genuity |